Issue link: https://uberflip.scri.com/i/1529641
1125/24SCR018-7/R3 Abstract & Presentation Calendar ASH® 2024 2 Saturday Sunday Monday SATURDAY, DECEMBER 7 TH 5:30pm - 7:00pm Pacific Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 2268 Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey Jacobs R (Burke JM presenting) Fletcher L, Burke J Health Services and Quality Improvement: Lymphoid Malignancies: Poster I 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 2300 Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System Cox T Cox T, Blunk B, Billups R, Meissner S, Sowell H, Larson S, Perez M, Ramakrishnan A, Shaughnessy P, Smith A, Tees MT, Pantin J, Majhail M, Battiwalla M Health Services and Quality Improvement: Myeloid Malignancies: Poster I 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 2080 Safety and Tolerability of BCMA- Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease Miljkovic MD Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 1873 Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax and Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial Sportoletti P Sharman JP Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 1975 Talquetamab, a GPRC5D—CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study Nooka AK Matous JV Multiple Myeloma: Pharmacologic Therapies: Poster I 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 1105 Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea Bencheikh L Frangoul H Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 1840 PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study Grieselhuber NR Rotta M Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 2068 NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL) Ahmed S Essell JH Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I